FLG and ovarian carcinoma: The somatic mutation analysis indicated that exceptional responders are more likely to have nonsynonymous mutations in FLG. Overexpression of FLG is associated with low immune cell infiltration and early patient mortality in melanoma and ovarian cancer [15], while loss of function mutations in FLG are associated with lower cancer risk among some subpopulations [16].